HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schrama, D. Articles by Becker, J. C. Search for Related Content PubMed PubMed Citation Articles by Schrama, D. Articles by Becker, J. C.

Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-2¹

David Schrama^*, Rong Xiang, Andreas O. Eggert^*, Mads Hald Andersen, Lars Østergaard Pedersen, Eckhart Kämpgen^*, Ton N. Schumacher, Ralph R. Reisfeld and Jürgen C. Becker^2,*

^* Department of Dermatology, Julius-Maximilians University, Würzburg, Germany; The Scripps Research Institute, La Jolla, CA 92037; Department of Tumor Cell Biology, Division of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; and Department of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

IL-2 has been approved for treatment of patients with cancer. Moreover, it has been used as a component of vaccines against cancer. In this regard, we have recently demonstrated that dendritic cell-based peptide vaccination in mice required IL-2 to mount an effective immune response against established melanoma metastases. In this study, we confirm this observation by use of tumor-targeted IL-2. However, the development of a protective systemic memory was substantially impaired by this measure, i.e., mice, which successfully rejected s.c. tumors of B16 melanoma after vaccination with dendritic cells pulsed with tyrosinase-related protein 2-derived peptides plus a boost with targeted IL-2, failed to reject a rechallenge with experimental pulmonary metastases. Detailed analysis revealed a change in the distribution of the tumor-reactive T cell population: although targeted IL-2 expanded the local effector population, tyrosinase-related protein 2-reactive T cells were almost completely depleted from lymphatic tissues.

This article has been cited by other articles:

				W. W. Overwijk, K. E. de Visser, F. H. Tirion, L. A. de Jong, T. W. H. Pols, Y. U. van der Velden, J. G. van den Boorn, A. M. Keller, W. A. Buurman, M. R. Theoret, et al. Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant J. Immunol., May 1, 2006; 176(9): 5213 - 5222. [Abstract] [Full Text] [PDF]